A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis

NCT01722461 | Terminated DMC

• 1 other identifier: ULT-119
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 6

Brief Summary

This is a prospective, multi-center, randomized, double-blinded study. Subjects enrolled will be randomly assigned to receive either active treatments for axillary hyperhidrosis with the Ulthera System in both axillas, or sham treatments, also with the Ulthera System but with the energy settings on the device set to deliver no ultrasound energy. Subjects will be randomized in a 2:1 ratio, with 2 subjects randomized to active treatment for every one subject randomized to sham treatment. Subjects will receive 2 study treatments 30 days apart. Subjects and study personnel conducting efficacy measures will be blinded to the assigned treatment groups. The study hypothesis is that subjects in the active treatment group will have a greater reduction in underarm sweating compared to those in the sham group as measured by a quality of life questionnaire. All subjects will undergo follow-up assessments at 14 days and 30 days from the date of their first study treatment, and 14 days, 30 days, 3 months and 6 months from the date of their second study treatment. Subjects in the active treatment group will also undergo follow-up assessments at 9 months and 12 months from the date of their second study treatment.

Conditions

Primary Axillary Hyperhidrosis

Keywords

Excessive underarm sweating

Outcome Measures

Primary Outcomes (1)

• Percentage of active treated subjects compared to sham treated subjects with reduced underarm sweating

  As measured by the Hyperhidrosis Disease Severity Scale (HDSS), a quality of life questionnaire

  30 days post-treatment #2

Secondary Outcomes (4)

• Percentage of active treated subjects compared to sham treated subjects with reduced underarm sweating

  6 month post treatment #2

• Percentage of active treated subjects compared to sham treated subjects with reduced underarm sweating

  12 months post treatment #2

• Percentage of active treated subjects compared to sham treated subjects with reduced average spontaneous axillary sweat production

  3 months post treatment

• Percentage of active treated subjects compared to sham treated subjects with reduced spontaneous axillary sweat production

  Subjects will be followed to 12 months post treatment #2

Study Arms (2)

Active treatment

EXPERIMENTAL

Ulthera System treatment

Device: Ulthera System

Sham treatment

SHAM COMPARATOR

Ulthera System delivering no ultrasound energy

Device: Sham treatment

Interventions

Ulthera System DEVICE

Focused ultrasound energy delivered below the surface of the skin

Also known as: Ultherapy™

Active treatment

Sham treatment DEVICE

Ulthera System delivering no ultrasound energy

Sham treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female, age 18 years or older.
• Subject is in good health.
• Diagnosis of primary focal axillary hyperhidrosis evidenced by at least two of the standard criteria.
• At least 50mg at 5 min of spontaneous resting axillary sweat production in each axilla measured gravimetrically
• A HDSS score of 3 or 4
• Willingness to comply with study visits and requirements
• Female subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at Visit 1
• Female subjects over 40 years of age must have had a mammogram in the last 2 years

You may not qualify if:

• Has a dermal disorder including infection at anticipated treatment sites in either axilla.
• Has had axillary injections of botulinum toxin in the last year.
• Has an expected use of botulinum toxin for the treatment of any other disease during the study period.
• Has a known allergy to starch powder, iodine, or lidocaine.
• Has secondary hyperhidrosis
• Has had previous surgical treatment of hyperhidrosis
• Has had prior miraDry treatment for axillary hyperhidrosis.
• Has used prescription antiperspirants in the last 14 days or plans to use them during the study period.
• Inability to withhold use of non-study-supplied antiperspirants and deodorants
• Unwillingness to wash off study-supplied antiperspirants and abstain from use for 72 hours prior to treatments or assessments.
• History of previous Ultherapy™ treatment to the axilla.
• Has a history of a bleeding disorder
• Has used of cholinomimetics, anticholinergics, or any oral herbal medicine treatments for hyperhidrosis in the past 4 weeks.
• Is a prisoner or under incarceration.
• Is participating in another clinical trial involving the use of investigational devices or drugs (or has in the last 30 days.)

Sponsors & Collaborators

• Ulthera, Inc: lead

Study Sites (6)

Roseville Facial Plastic Surgery

Roseville, California, 95661, United States

Location

The Center for Clinical and Cosmetic Research

Aventura, Florida, 33180, United States

Location

Few Institute of Aesthetic Plastic Surgery

Chicago, Illinois, 60611, United States

Location

St Louis University Dermatology

St Louis, Missouri, 63104, United States

Location

Day Dermatology & Aesthetics

New York, New York, 10021, United States

Location

Virginia Clinical Research

Norfolk, Virginia, 23507, United States

Location

Study Officials

• Mark S Nestor, M.D., Ph.D

  The Center for Clinical and Cosmetic Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 2, 2012
• First Posted: November 6, 2012
• Study Start: November 1, 2012
• Primary Completion: May 1, 2013
• Study Completion: November 1, 2013
• Last Updated: November 24, 2017

Record last verified: 2013-12

Locations

US (6)